News
-
-
PRESS RELEASE
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Sanofi's two combination vaccine candidates targeting influenza and COVID-19 granted Fast Track designation in the US. Candidates combine licensed vaccines to assess safety and immunogenicity in older adults -
-
PRESS RELEASE
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New data presented at ASH demonstrates significant clinical benefit with Sarclisa-based combinations in newly diagnosed multiple myeloma patients, highlighting deep and durable responses and improved outcomes -
-
PRESS RELEASE
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted -
-
PRESS RELEASE
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025 -
-
